Quick Answer
Armata Pharmaceuticals, Inc. reported R&D Expense of $9.82 million for fiscal year 2019.
Armata Pharmaceuticals, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2019 | $9.82M | +17.3% |
| 2018 | $8.37M | +190.6% |
| 2017 | $2.88M | -49.3% |
| 2016 | $5.68M | +42.2% |
| 2015 | $3.99M | -31.2% |
| 2014 | $5.80M | -10.3% |
| 2013 | $6.47M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| March 31, 2019 | $1.49M | +2.0% | +313.9% |
| September 30, 2018 | $361.0K | — | -78.7% |
| June 30, 2018 | $1.69M | +49.7% | +15.6% |
| March 31, 2018 | $1.46M | -1.7% | +29.6% |
| June 30, 2017 | $1.13M | -8.9% | -24.2% |
| March 31, 2017 | $1.49M | -24.7% | -10.0% |
| September 30, 2016 | $1.66M | +127.3% | +33.4% |
| June 30, 2016 | $1.24M | +15.2% | -37.3% |
- Armata Pharmaceuticals, Inc. showed an increase of +17.3% in R&D Expense compared to the prior fiscal year.
- Over the 2013–2019 period, Armata Pharmaceuticals, Inc.’s r&d expense has grown by 51.9% (from $6.47 million to $9.82 million).
- The most recent figure is from Armata Pharmaceuticals, Inc.’s fiscal year 2019 report (Form 10-K), filed with the SEC on March 19, 2020.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: